Healthcare
AstraZeneca and Oracle team up on AI platform for clinical trials
AstraZeneca and Oracle announced an AI platform initiative for clinical research, beginning with hypertension care and trial recruitment in Abu Dhabi through M42.
AstraZeneca and Oracle announced an AI-focused clinical-research project whose first program will run in Abu Dhabi with M42. The initiative aims to identify people with uncontrolled hypertension, connect them with guideline-directed care, and improve recruitment into clinical trials. The companies said the broader collaboration may also support earlier diagnosis, drug-safety monitoring, and the use of real-world evidence throughout the medicine lifecycle. Future projects are expected to cover oncology, cardiovascular, renal and metabolic diseases, respiratory and immunology conditions, and rare diseases across the United States, Europe, and the Middle East. The announcement builds on Oracle’s health-data and cloud capabilities and AstraZeneca’s drug-development expertise. It matters because clinical-trial recruitment is a persistent operational challenge: eligible patients can be difficult to identify, while relevant clinical information is distributed across care systems. Applying AI within clinical workflows could reduce screening effort and connect routine treatment with research participation. The source characterises the agreement as a project intended to test practical applications, not as evidence of completed patient outcomes.
Original source: Pharmaphorum